Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited

被引:12
|
作者
Derchi, Giorgio [1 ]
Dessi, Carlo [2 ]
Bina, Patrizio [2 ]
Cappellini, Maria Domenica [3 ]
Piga, Antonio [4 ]
Perrotta, Silverio [5 ]
Tartaglione, Immacolata [5 ]
Giuditta, Marianna [3 ]
Longo, Filomena [4 ]
Origa, Raffaella [6 ]
Quarta, Antonella [7 ]
Pinto, Valeria [8 ]
Forni, Gian Luca [8 ]
机构
[1] Osped Galliera, Unita Cardiol, Genoa, Italy
[2] Osped Reg Microcitemie, ASL8, Cagliari, Italy
[3] Univ Milan, Dept Clin Sci & Commun, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Milan, Italy
[4] Univ Torino, Dept Clin & Biol Sci, Turin, Italy
[5] Seconda Univ Napoli, Dipartimento Donna Bambino Chirurg Gen & Speciali, Naples, Italy
[6] Univ Cagliari, Thalassemia Unit, Dept Publ Hlth Clin & Mol Med, Cagliari, Italy
[7] Ematol Osped A Perrino, Brindisi, Italy
[8] Osped Galliera, Ematol Ctr Microcitemia & Anemie Congenite, Via Volta 6, I-16128 Genoa, Italy
关键词
Thalassemia; Heart disease; Iron overload; Serum ferritin; RANDOMIZED CONTROLLED-TRIAL; MAJOR PATIENTS; IRON OVERLOAD; MYOCARDIAL IRON; FOLLOW-UP; DEFEROXAMINE; DEFERASIROX; MANAGEMENT; COMPLICATIONS; DEFERIPRONE;
D O I
10.1007/s11739-018-1890-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart disease remains a leading cause of morbidity and mortality in transfusion-dependent thalassemia (TDT), which can be attributed to several factors but primarily develops in the setting of iron overload. This was a retrospective cohort study utilizing Webthal (R) patient data from five major centers across Italy. Patients without heart disease were followed-up for 10 years (2000-2010) and data were collected for demographics, splenectomy status, serum ferritin and hemoglobin levels, and comorbidities associated with heart disease. Among 379 patients analyzed (mean age 22.9 +/- 5.1years, 47.8% men), 44 (cumulative incidence: 11.6%) developed heart disease during the period of observation. Splenectomy (p=0.002) and serum ferritin level (p<0.001) were the only risk factors with significant association with heart disease. A serum ferritin threshold of >= 3000 ng/mL was the best predictor for the development of heart disease (86.4% sensitivity and 92.8% specificity, AUC: 0.912, 95% CI 0.852-0.971, p<0.001). On multivariate analysis, only a serum ferritin level >= 3000 ng/mL remained significantly and independently associated with increased risk of heart disease (HR: 44.85, 95% CI 18.85-106.74), with a 5- and 10-year heart disease-free survival of 58 and 39%. The association between iron overload and heart disease in patients with TDT is confirmed, yet a new serum ferritin level of 3000 ng/mL to flag increased risk is suggested.
引用
收藏
页码:365 / 370
页数:6
相关论文
共 50 条
  • [21] Hypoparathyroidism in transfusion-dependent patients with β-thalassemia
    Angelopoulos, NG
    Goula, A
    Rombopoulos, G
    Kaltzidou, V
    Katounda, E
    Kaltsas, D
    Tolis, G
    JOURNAL OF BONE AND MINERAL METABOLISM, 2006, 24 (02) : 138 - 145
  • [22] Hypoparathyroidism in transfusion-dependent patients with β-thalassemia
    Nicholas G. Angelopoulos
    Anastasia Goula
    Grigorios Rombopoulos
    Victoria Kaltzidou
    Eugenia Katounda
    Dimitrios Kaltsas
    George Tolis
    Journal of Bone and Mineral Metabolism, 2006, 24 : 138 - 145
  • [23] Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT)
    Maira, D.
    Cassinerio, E.
    Marcon, A.
    Mancarella, M.
    Fraquelli, M.
    Pedrotti, P.
    Cappellini, M. D.
    ANNALS OF HEMATOLOGY, 2017, 96 (11) : 1931 - 1936
  • [24] Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
    Forni, Gian Luca
    Kattamis, Antonis
    Kuo, Kevin H. M.
    Maggio, Aurelio
    Sheth, Sujit
    Taher, Ali T.
    Viprakasit, Vip
    PEDIATRIC BLOOD & CANCER, 2024, 71 (08)
  • [25] Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia
    Porter, John B.
    Elalfy, Mohsen
    Taher, Ali
    Aydinok, Yesim
    Lee, Szu-Hee
    Sutcharitchan, Pranee
    El-Ali, Ali
    Han, Jackie
    El-Beshlawy, Amal
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (03) : 280 - 288
  • [26] Iranian experience of deferasirox (Exjade®) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
    Karimi, Mehran
    Azarkeivan, Azita
    Zareifar, Soheila
    Cohan, Nader
    Bordbar, Mohammad Reza
    Haghpanah, Sezaneh
    HEMATOLOGY, 2012, 17 (06) : 367 - 371
  • [27] Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East
    El-Beshlawy, Amal
    Dewedar, Hany
    Hindawi, Salwa
    Alkindi, Salam
    Tantawy, Azza A.
    Yassin, Mohamed A.
    Taher, Ali T.
    BLOOD REVIEWS, 2024, 63
  • [28] Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study
    Musallam, Khaled M.
    Cappellini, Maria Domenica
    Daar, Shahina
    Karimi, Mehran
    El-Beshlawy, Amal
    Graziadei, Giovanna
    Magestro, Matthew
    Wulff, Jerome
    Pietri, Guilhem
    Taher, Ali T.
    HAEMATOLOGICA, 2014, 99 (11)
  • [29] Physical growth in children with transfusion-dependent thalassemia
    Pemde, Harish K.
    Chandra, Jagdish
    Gupta, Divya
    Singh, Varinder
    Sharma, Rajni
    Dutta, A. K.
    PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2011, 2 : 13 - 19
  • [30] Hypogonadism among patients with transfusion-dependent thalassemia: a cross-sectional study
    Mahwi, Taha O.
    Rashid, Zagros G.
    Ahmed, Shaho F.
    ANNALS OF MEDICINE AND SURGERY, 2023, 85 (07): : 3418 - 3422